Niapelf (Paliperidone)

Paliperidone acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, which helps to balance neurotransmission implicated in psychosis. It also blocks α1‑adrenergic, H1‑histamine and 5‑HT7 receptors, contributing to its antipsychotic and mood‑stabilising effects.

The dosing regimen for Niapelf is individualized by the prescribing clinician based on the patient’s clinical status, prior treatment response, and tolerability. The prescriber determines the appropriate injection volume, frequency and any necessary titration.

The safety of paliperidone in pregnancy and lactation has not been definitively established; it is classified as pregnancy category unknown. Use only if the potential benefit justifies the potential risk, and discuss with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Compared with oral atypical antipsychotics, Niapelf offers a long‑acting intramuscular option that can improve adherence and provide steady plasma levels. Its receptor profile is similar to other paliperidone or risperidone products, but the injectable form avoids daily oral dosing.

Niapelf should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the product, and keep it out of reach of children.

The medication is given by a healthcare professional as an intramuscular injection, typically into the deltoid or gluteal muscle. The injection site should be rotated as directed, and aseptic technique must be observed.

Serious adverse reactions can include neuroleptic malignant syndrome, tardive dyskinesia, severe hypotension, myocarditis, agranulocytosis and seizures. Patients should be monitored closely for any signs of these conditions and seek immediate medical attention if they occur.

Niapelf is contraindicated in patients with known hypersensitivity to paliperidone or any excipients, and should be used with caution in individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome. Consultation with a clinician is required before initiation.